Frazier Life Sciences Reduces Stake by $83.8M Amidst Tender Offer
KALV has more than doubled off its 52-week low of $9.83.
Summary
Frazier Life Sciences has sold a significant portion of its holdings in KalVista Pharmaceuticals, totaling $83.8 million, as the company undergoes an acquisition by Chiesi Group.
Key Events · Ownership and Investor Activity · KALV
-
Major Stake Reduction
Frazier Life Sciences and its affiliated funds sold a total of 3,130,805 shares of KalVista Pharmaceuticals common stock.
-
Significant Transaction Value
The sales, executed on May 6 and May 19, 2026, totaled approximately $83.8 million, representing about 5.88% of the company's outstanding shares.
-
Strategic Exit Amidst Acquisition
These transactions occurred after the April 29, 2026 announcement of KalVista's acquisition by Chiesi Group for $27.00 per share, and during the subsequent tender offer period, indicating a strategic move by the institutional investor.
-
Current Ownership
After these sales, Frazier Life Sciences' combined beneficial ownership has decreased to 1,829,303 shares, or 3.44% of the outstanding common stock.
Analysis · KALV · Life Sciences
Frazier Life Sciences, a significant institutional investor, has substantially reduced its stake in KalVista Pharmaceuticals by selling over 3.1 million shares for approximately $83.8 million. These sales occurred after the announcement of Chiesi Group's acquisition offer and during the ongoing tender offer at $27.00 per share, indicating a strategic exit by the fund as the company is being acquired.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KALV was trading at $26.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $9.83 to $26.85. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.